查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1421685

重症肌無力治療市場、份額、規模、趨勢、行業分析報告：按藥物類別、按診斷、按治療、按分銷渠道、按地區、按細分市場、預測，2024-2032 年

Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，到2032年，全球重症肌無力治療市場規模預計將達到23.2億美元。 該報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

重症肌無力是一種自體免疫神經肌肉疾病，免疫系統攻擊神經和肌肉之間的連接，導致肌肉無力和疲勞。

由於多種因素，重症肌無力 (MG) 治療市場近年來穩定成長。 其中包括診斷數量的增加、對疾病的更深入了解以及治療方法的進步。 製藥公司也正在投資研發，以推出更有效且副作用更少的創新療法。 隨著生物製劑和分子標靶治療的出現，對更安全、更有效的治療的需求預計將繼續推動全球重症肌無力治療市場的成長。

COVID-19 大流行對重症肌無力 (MG) 疾病市場產生了重大影響。 由於醫療保健系統集中在 COVID-19 患者，導致診斷和治療延誤，MG 面臨挑戰。 然而，大流行加速了遠距醫療和遠端監控的使用，為重症肌無力患者諮詢醫療保健專業人員提供了重要工具，同時最大限度地減少了病毒暴露。 儘管有這種幹擾，製藥業仍在繼續開發重症肌無力的新療法，為改善治療方案帶來了希望。

此外，國家醫學圖書館 2021 年 6 月發表的一項研究強調了冠狀動脈疾病 (CAD) 對全球健康的重大影響。 光是 CAD 每年就導致約 61 萬人死亡，佔估計死亡人數的四分之一，是美國的第一大死因。 隨著 CAD 發生率的增加，對有效的冠狀動脈支架裝置的需求不斷增長，以滿足這一緊迫的醫療需求。 因此，預計這一因素將在預測期內推動冠狀動脈支架的需求。

重症肌無力市場報告重點

  • 2022 年，IVIG 細分市場在重症肌無力市場中佔據最大的銷售份額。 靜脈注射免疫球蛋白治療 (IVIg) 涉及輸注從健康捐贈者獲得的免疫球蛋白抗體。 人們發現這種醫療程序對於暫時調節免疫系統和控制重症肌無力 (MG) 症狀非常有效。
  • 在預測期內，醫院部門佔據了最高的市場份額。 醫院藥局透過分發和使用各種藥物，在重症肌無力 (MG) 的治療中發揮重要作用。 隨著重症肌無力病例數的增加，越來越多的患者在醫院接受治療，增加了醫院藥局對重症肌無力專用藥物的需求。
  • 2022 年，北美佔據最大市場。 重症肌無力（MG）在北美有顯著的盛行率，且北美在治療中佔有重要地位。 該地區強大的醫療基礎設施有助於識別和管理大量重症肌無力患者，這引起了製藥公司和研究人員的興趣。 此外，有彈性的醫療報銷框架有效擴大了許多昂貴的重症肌無力治療的覆蓋範圍，增加了患者的可及性並促進及時幹預。
  • 亞太地區是肌無力治療市場成長最快的地區。 該市場的成長受到多種因素的推動，其中最引人注目的是公共和私人機構的合作努力。 這些努力主要集中在開發和傳播神經肌肉疾病的有效治療方法。 此外，透過教育活動和資訊傳播努力提高大眾對神經肌肉疾病的認識也推動了市場的擴張。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球重症肌無力治療市場洞察

  • 重症肌無力治療 - 產業概況
  • 重症肌無力治療市場動態
    • 推動者和機會
      • 全球治療方法和治療選擇的改進推動了市場成長
      • 醫療基礎建設費用上漲推動市場成長
    • 抑制因素和挑戰
      • 高昂的處理成本阻礙了市場成長
  • 杵分析
  • 重症肌無力治療產業的趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第 5 章全球重症肌無力治療市場（依藥物類別）

  • 主要發現
  • 簡介
  • IVIg
  • 單株抗體
  • 免疫抑制劑
  • 膽鹼酯□抑制劑
  • 皮質類固醇

第 6 章全球重症肌無力治療市場（依診斷）

  • 主要發現
  • 簡介
  • 驗血
  • 電氣診斷
  • 依酚銨測試

第七章全球重症肌無力治療市場（依治療）

  • 主要發現
  • 簡介
  • 手術
  • 藥品
  • 造血幹細胞移植

第 8 章全球重症肌無力治療市場（依通路）

  • 主要發現
  • 簡介
  • 網路藥局
  • 醫院藥房
  • 零售藥局

第 9 章全球重症肌無力治療市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年重症肌無力治療市場評估，地區
  • 重症肌無力治療市場 - 北美
    • 北美：重症肌無力治療市場，依藥物類別，2019-2032 年
    • 北美：重症肌無力治療市場，依通路劃分，2019-2032 年
    • 北美：2019-2032 年重症肌無力治療市場（依診斷）
    • 北美：重症肌無力治療市場（依治療方式），2019-2032 年
    • 重症肌無力治療市場 - 美國
    • 重症肌無力治療市場 - 加拿大
  • 重症肌無力治療市場 - 歐洲
    • 歐洲：2019-2032 年重症肌無力治療市場（依藥物類別）
    • 歐洲：重症肌無力治療市場，依通路劃分，2019-2032 年
    • 歐洲：2019-2032 年重症肌無力治療市場（依診斷）
    • 歐洲：重症肌無力治療市場（依治療方式），2019-2032 年
    • 重症肌無力治療市場 - 英國
    • 重症肌無力治療市場 - 法國
    • 重症肌無力治療市場 - 德國
    • 重症肌無力治療市場 - 義大利
    • 重症肌無力治療市場 - 西班牙
    • 重症肌無力治療市場 - 荷蘭
    • 重症肌無力治療市場 - 俄羅斯
  • 重症肌無力治療市場 - 亞太地區
    • 亞太地區：重症肌無力治療市場，依藥物類別，2019-2032 年
    • 亞太地區：重症肌無力治療市場（依通路），2019-2032 年
    • 亞太地區：2019-2032 年重症肌無力治療市場（依診斷）
    • 亞太地區：重症肌無力治療市場（依治療方式），2019-2032 年
    • 重症肌無力治療市場 - 中國
    • 重症肌無力治療市場 - 印度
    • 重症肌無力治療市場 - 日本
    • 重症肌無力治療市場 - 馬來西亞
    • 重症肌無力治療市場 - 印度尼西亞
    • 重症肌無力治療市場 - 韓國
  • 重症肌無力治療市場 - 中東和非洲
    • 中東和非洲：2019-2032 年重症肌無力治療市場（依藥物類別）
    • 中東與非洲：重症肌無力治療市場（依通路），2019-2032 年
    • 中東與非洲：2019-2032 年重症肌無力治療市場（依診斷）
    • 中東與非洲：重症肌無力治療市場（依治療方式），2019-2032 年
    • 重症肌無力治療市場 - 沙烏地阿拉伯
    • 重症肌無力治療市場 - 南非
    • 重症肌無力治療市場 - 以色列
    • 重症肌無力治療市場 - 阿聯酋
  • 重症肌無力治療市場 - 拉丁美洲
    • 拉丁美洲：重症肌無力治療市場，依藥物類別，2019-2032 年
    • 拉丁美洲：重症肌無力治療市場，依通路劃分，2019-2032 年
    • 拉丁美洲：2019-2032 年重症肌無力治療市場（依診斷）
    • 拉丁美洲：重症肌無力治療市場（依治療方式），2019-2032 年
    • 重症肌無力治療市場 - 墨西哥
    • 重症肌無力治療市場 - 巴西
    • 重症肌無力治療市場 - 阿根廷

第10章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第十一章公司簡介

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.（formerly Valeant Pharmaceuticals）
  • Bristol-Myers Squibb Company（now part of Bristol Myers Squibb）
  • Grifols, S.A.
  • Mylan N.V.（now part of Viatris Inc.）
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holdings AG（including its subsidiary, Genentech）
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: PM4026

The global myasthenia gravis disease treatment market size is expected to reach USD 2.32 billion by 2032, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia gravis is an autoimmune neuromuscular disorder that causes muscle weakness and fatigue due to the immune system attacking the connection between nerves and muscles.

The market for treating Myasthenia Gravis (MG) has been growing steadily in recent years due to several factors. There has been an increase in the number of diagnoses, better understanding of the disease, and advancements in treatment options. Pharmaceutical companies have also invested in research and development to introduce innovative therapies that offer more effectiveness and fewer side effects. With the emergence of biologics and targeted therapies, the demand for safer and more efficient treatments is expected to continue driving the growth of the global MG treatment market.

The COVID-19 pandemic had a significant impact on the Myasthenia Gravis (MG) disease market. MG faced challenges due to the healthcare system's focus on COVID-19 patients, causing delays in diagnosis and treatment. However, the pandemic accelerated the use of telemedicine and remote monitoring, which provided crucial tools for MG patients to consult with healthcare providers while minimizing virus exposure. The pharmaceutical industry continued to develop novel therapies for MG despite disruptions, offering hope for improved treatment options.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective coronary stent devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for coronary stents throughout the forecast period.

Myasthenia Gravis Disease Market Report Highlights

  • In 2022, the IVIg segment held the largest revenue share in the myasthenia gravis disease market. Intravenous Immunoglobulin (IVIg) treatment involves the infusion of immunoglobulin antibodies obtained from healthy donors. This medical procedure has been found to be highly effective in temporarily regulating the immune system and managing the symptoms of Myasthenia Gravis (MG).
  • The hospital segment accounted for the highest market share during the forecast period. Hospital pharmacies play a vital role in managing Myasthenia Gravis (MG) through the distribution and application of various medications. As MG cases increase, more patients seek treatment in hospitals, leading to a higher demand for MG-specific drugs in hospital pharmacies.
  • In 2022, North America dominated the largest market. Myasthenia gravis (MG) exhibits a significant prevalence in North America, positioning it as a key player in the landscape of treatment. The region's robust healthcare infrastructure facilitates the identification and management of a substantial number of MG cases, drawing the interest of pharmaceutical firms and researchers alike. Furthermore, the resilient healthcare reimbursement framework effectively extends coverage to numerous costly MG treatments, enhancing their accessibility for patients and promoting prompt intervention.
  • The Asia-Pacific region accounted for the fastest growth in the myasthenia disease treatment market. The market's growth is driven by various factors, notably the concerted efforts of both public and private entities. These endeavors primarily focus on advancing and distributing effective treatments for neuromuscular disorders. Moreover, the market's expansion is fueled by increasing public awareness of neuromuscular conditions, supported by educational campaigns and information dissemination initiatives.
  • The global key market players include: AbbVie Inc., Alexion Pharmaceuticals, Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Grifols, S.A., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holdings AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the myasthenia disease treatment market report based on drug class, diagnosis, treatment, distribution channel, and region:

Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • IVIg
  • Monoclonal Antibodies
  • Immunosuppressants
  • Cholinesterase Inhibitors
  • Corticosteroids

Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

  • Blood Tests
  • Electrodiagnosis
  • Edrophonium Test

Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Surgery
  • Medication
  • HSCT

Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Treatment Market Insights

  • 4.1. Myasthenia Gravis Disease Treatment - Industry Snapshot
  • 4.2. Myasthenia Gravis Disease Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Improvement in therapies and treatment options across the Globe will Facilitate market growth
      • 4.2.1.2. Inflation of healthcare infrastructure bill bolster market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High treatment cost will hamper on the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Myasthenia Gravis Disease Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. IVIg
    • 5.3.1. Global Myasthenia Gravis Disease Treatment Market, by IVIg, by Region, 2019-2032 (USD Billion)
  • 5.4. Monoclonal Antibodies
    • 5.4.1. Global Myasthenia Gravis Disease Treatment Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
  • 5.5. Immunosuppressants
    • 5.5.1. Global Myasthenia Gravis Disease Treatment Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
  • 5.6. Cholinesterase Inhibitors
    • 5.6.1. Global Myasthenia Gravis Disease Treatment Market, by Cholinesterase Inhibitors, by Region, 2019-2032 (USD Billion)
  • 5.7. Corticosteroids
    • 5.7.1. Global Myasthenia Gravis Disease Treatment Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)

6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • 6.3. Blood Tests
    • 6.3.1. Global Myasthenia Gravis Disease Treatment Market, by Blood Tests, by Region, 2019-2032 (USD Billion)
  • 6.4. Electrodiagnosis
    • 6.4.1. Global Myasthenia Gravis Disease Treatment Market, by Electrodiagnosis, by Region, 2019-2032 (USD Billion)
  • 6.5. Edrophonium Test
    • 6.5.1. Global Myasthenia Gravis Disease Treatment Market, by Edrophonium Test, by Region, 2019-2032 (USD Billion)

7. Global Myasthenia Gravis Disease Treatment Market, by Treatment

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 7.3. Surgery
    • 7.3.1. Global Myasthenia Gravis Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 7.4. Medication
    • 7.4.1. Global Myasthenia Gravis Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)
  • 7.5. HSCT
    • 7.5.1. Global Myasthenia Gravis Disease Treatment Market, by HSCT, by Region, 2019-2032 (USD Billion)

8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3. Online Pharmacies
    • 8.3.1. Global Myasthenia Gravis Disease Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Global Myasthenia Gravis Disease Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.5. Retail Pharmacies
    • 8.5.1. Global Myasthenia Gravis Disease Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)

9. Global Myasthenia Gravis Disease Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Myasthenia Gravis Disease Treatment Market - North America
    • 9.3.1. North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.2. North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3. North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.3.4. North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.3.5. Myasthenia Gravis Disease Treatment Market - U.S.
      • 9.3.5.1. U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.3.6. Myasthenia Gravis Disease Treatment Market - Canada
      • 9.3.6.1. Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.4. Myasthenia Gravis Disease Treatment Market - Europe
    • 9.4.1. Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.5. Myasthenia Gravis Disease Treatment Market - UK
      • 9.4.5.1. UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.6. Myasthenia Gravis Disease Treatment Market - France
      • 9.4.6.1. France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.7. Myasthenia Gravis Disease Treatment Market - Germany
      • 9.4.7.1. Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.8. Myasthenia Gravis Disease Treatment Market - Italy
      • 9.4.8.1. Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.9. Myasthenia Gravis Disease Treatment Market - Spain
      • 9.4.9.1. Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.10. Myasthenia Gravis Disease Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.11. Myasthenia Gravis Disease Treatment Market - Russia
      • 9.4.11.1. Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.5. Myasthenia Gravis Disease Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.5. Myasthenia Gravis Disease Treatment Market - China
      • 9.5.5.1. China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.6. Myasthenia Gravis Disease Treatment Market - India
      • 9.5.6.1. India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.7. Myasthenia Gravis Disease Treatment Market - Japan
      • 9.5.7.1. Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.8. Myasthenia Gravis Disease Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.9. Myasthenia Gravis Disease Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.10. Myasthenia Gravis Disease Treatment Market - South Korea
      • 9.5.10.1. South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.6. Myasthenia Gravis Disease Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.5. Myasthenia Gravis Disease Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.6. Myasthenia Gravis Disease Treatment Market - South Africa
      • 9.6.6.1. South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.7. Myasthenia Gravis Disease Treatment Market - Israel
      • 9.6.7.1. Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.8. Myasthenia Gravis Disease Treatment Market - UAE
      • 9.6.8.1. UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.7. Myasthenia Gravis Disease Treatment Market - Latin America
    • 9.7.1. Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.5. Myasthenia Gravis Disease Treatment Market - Mexico
      • 9.7.5.1. Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.6. Myasthenia Gravis Disease Treatment Market - Brazil
      • 9.7.6.1. Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.7. Myasthenia Gravis Disease Treatment Market - Argentina
      • 9.7.7.1. Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. AbbVie Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Alexion Pharmaceuticals, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Grifols, S.A.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Mylan N.V. (now part of Viatris Inc.)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Novartis AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Pfizer Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Regeneron Pharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Roche Holdings AG (including its subsidiary, Genentech)
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Takeda Pharmaceutical Company Limited
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Teva Pharmaceutical Industries Ltd.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development

List of Tables

  • Table 1 Global Myasthenia Gravis Disease Treatment Market, by Drug Class, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Myasthenia Gravis Disease Treatment Market, by Treatment, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
  • Table 5 Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 7 North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 8 North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 9 North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 10 U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 11 U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 12 U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 16 Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 17 Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 18 Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 19 Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 20 Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 21 Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 22 Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 23 Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 24 Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 28 France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 29 France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 30 UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 31 UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 32 UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 33 UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 34 Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 35 Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 36 Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 42 Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 43 Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 44 Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 45 Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 46 Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 47 Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 48 Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Russia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 54 China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 55 China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 56 China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 57 China: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 58 Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 59 Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 60 Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Japan: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 64 India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 65 India: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 76 South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 77 South Korea: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 78 Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 79 Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 80 Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 81 Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 82 Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 83 Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 84 Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 86 Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 87 Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 88 Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 89 Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 90 Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 91 Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 92 Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 93 Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 98 UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 99 UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 100 UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 101 UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 106 South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 107 South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 108 South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 109 South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 110 Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 111 Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 112 Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 113 Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Myasthenia Gravis Disease Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Diagnosis
  • Figure 11. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Treatment
  • Figure 13. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2021 & 2030 (USD Billion)